Approaches to inverse-probability-of-treatment--weighted estimation with concurrent treatments
- PMID: 23849154
- DOI: 10.1016/j.jclinepi.2013.03.020
Approaches to inverse-probability-of-treatment--weighted estimation with concurrent treatments
Abstract
Objectives: In a setting with two concurrent treatments, inverse-probability-of-treatment weights can be used to estimate the joint treatment effects or the marginal effect of one treatment while taking the other to be a confounder. We explore these two approaches in a study of intravenous iron use in hemodialysis patients treated concurrently with epoetin alfa (EPO).
Study design and setting: We linked US Renal Data System data with electronic health records (2004-2008) from a large dialysis provider. Using a retrospective cohort design with 776,203 records from 117,050 regular hemodialysis patients, we examined a composite outcome: mortality, myocardial infarction, or stroke.
Results: With EPO as a joint treatment, inverse-probability-of-treatment weights were unstable, confidence intervals for treatment effects were wide, covariate balance was unsatisfactory, and the treatment and outcome models were sensitive to omission of the baseline EPO covariate. By handling EPO exposure as a confounder instead of a joint treatment, we derived stable weights and balanced treatment groups on measured covariates.
Conclusions: In settings with concurrent treatments, if only one treatment is of interest, then including the other in the treatment model as a confounder may result in more stable treatment effect estimates. Otherwise, extreme weights may necessitate additional analysis steps.
Keywords: Epidemiologic methods; Estimation; Models; Propensity score; Statistical; Statistics as topic.
Copyright © 2013 Elsevier Inc. All rights reserved.
Similar articles
-
Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study.Am J Kidney Dis. 2015 Jul;66(1):106-13. doi: 10.1053/j.ajkd.2015.02.339. Epub 2015 May 2. Am J Kidney Dis. 2015. PMID: 25943715 Free PMC article.
-
Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis.Am J Kidney Dis. 2015 Jul;66(1):69-74. doi: 10.1053/j.ajkd.2014.12.012. Epub 2015 Jan 28. Am J Kidney Dis. 2015. PMID: 25636816 Free PMC article. Review.
-
Effectiveness of a pharmacist-implemented anemia management protocol in an outpatient hemodialysis unit.Am J Health Syst Pharm. 2001 Nov 1;58(21):2061-5. doi: 10.1093/ajhp/58.21.2061. Am J Health Syst Pharm. 2001. PMID: 11715828 No abstract available.
-
Association of mean weekly epoetin alfa dose with mortality risk in a retrospective cohort study of Medicare hemodialysis patients.Am J Nephrol. 2011;34(4):298-308. doi: 10.1159/000330693. Epub 2011 Aug 9. Am J Nephrol. 2011. PMID: 21829009
-
Effects of Epoetin alfa on hemostasis in chronic renal failure.Am J Nephrol. 1998;18(4):263-73. doi: 10.1159/000013349. Am J Nephrol. 1998. PMID: 9653828 Review.
Cited by
-
Comparison of Cefepime with Piperacillin/Tazobactam Treatment in Patients with Hospital-Acquired Pneumonia.Antibiotics (Basel). 2023 May 30;12(6):984. doi: 10.3390/antibiotics12060984. Antibiotics (Basel). 2023. PMID: 37370303 Free PMC article.
-
Modeling the impact of digital readiness in recruiting and sustaining underrepresented groups: Data from the All of Us research program.Front Digit Health. 2023 Apr 13;4:1082098. doi: 10.3389/fdgth.2022.1082098. eCollection 2022. Front Digit Health. 2023. PMID: 37124163 Free PMC article.
-
Statistical methods for non-adherence in non-inferiority trials: useful and used? A systematic review.BMJ Open. 2022 Jan 12;12(1):e052656. doi: 10.1136/bmjopen-2021-052656. BMJ Open. 2022. PMID: 35022173 Free PMC article.
-
Methodological Challenges and Proposed Solutions for Evaluating Opioid Policy Effectiveness.Health Serv Outcomes Res Methodol. 2021 Mar;21(1):21-41. doi: 10.1007/s10742-020-00228-2. Epub 2020 Nov 12. Health Serv Outcomes Res Methodol. 2021. PMID: 33883971 Free PMC article.
-
A biologist's guide to model selection and causal inference.Proc Biol Sci. 2021 Jan 27;288(1943):20202815. doi: 10.1098/rspb.2020.2815. Epub 2021 Jan 27. Proc Biol Sci. 2021. PMID: 33499782 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
